Cascara sagrada
This article was originally published in The Tan Sheet
Executive Summary
FDA should maintain inclusion of cascara sagrada bark in OTC laxatives monograph for adult use, while "use by children at the current recommended dose should be reconsidered" based on toxicity studies on emodin, The Toxicology Group says. In a report submitted to FDA by AHPA Dec. 19, NSF subsidiary presents safety conclusions for cascara based upon National Toxicology Program reports on toxicity of phenolphthalein, a Category II ingredient, and emodin, a constituent of cascara. "The structure of phenolphthalein and those of cascara sagrada's constituents are significantly dissimilar so that there is little reason to think that toxicity concerns for phenolphthalein should be extrapolated for cascara sagrada preparations," NSF division says. AHPA's submission is part of its citizen petition requesting FDA reconsider Category II designation for cascara (1"The Tan Sheet" Nov. 4, 2002, In Brief)...
You may also be interested in...
Cascara sagrada laxatives
AHPA "intends to submit a review document within the next several weeks that will evaluate the relevance" of published data pertaining to "the potential mutagenicity, genotoxicity and carcinogenicity of cascara sagrada ingredients," trade association tells FDA. In Oct. 28 submission, AHPA includes "eight summaries of literature searches conducted over the past several months" on cascara sagrada bark that were "not previously considered" by FDA's OTC Drug Products staff or agency's advisory review panel on OTC laxatives. Group is seeking a stay of Nov. 5 effective date of final rule classifying cascara sagrada, aloe as Category II laxative ingredients (1"The Tan Sheet" June 17, 2002, p. 7)...
Health And Wellness Trademark Review 2 March, 2021
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
In Order Shutting Down New York Supplement Firm, Federal Judge Also Criticizes FDA’s Calculations
Judge ordering permanent injunction against Confidence USA on a complaint filed in 2019 questioned FDA's calculations for requiring the firm to recall and destroy all products it had distributed since February 2018.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: